Lyell Immunopharma, Inc. (LYEL)

2,3900 -0,0100 (-0,42%) In data: 02:55PM EDT. Mercato aperto.

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 224

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Richard D. Klausner M.D.	Founder & Executive Chairman	80k	N/D	1952
Dr. Lynn Seely M.D., Ph.D.	President, CEO & Director	430,69k	N/D	1959
Mr. Charles W. Newton	Chief Financial Officer	1,72M	N/D	1971
Mr. Stephen J. Hill	Chief Operating Officer	1,04M	N/D	1970
Dr. Gary Lee Ph.D.	Chief Scientific Officer	639,91k	N/D	1977
Ms. Elizabeth Homans	Consultant	1,99M	N/D	1966
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor	N/D	N/D	N/D
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor	N/D	N/D	1961
Nellie Dillery	Director of Accounting	N/D	N/D	N/D
Ms. Ellen Rose	Senior Vice President of Communications & Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Lyell Immunopharma, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.